184 related articles for article (PubMed ID: 12113029)
1. Therapeutic advances in the management of metastatic colorectal cancer.
Freyer G; Ligneau B; Kraft D; Descos L; Trillet-Lenoir V
Expert Rev Anticancer Ther; 2001 Aug; 1(2):236-46. PubMed ID: 12113029
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy for colorectal cancers].
Lièvre A; Mitry E
J Chir (Paris); 2003 Feb; 140(1):52-5. PubMed ID: 12709655
[TBL] [Abstract][Full Text] [Related]
5. New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Holen KD; Saltz LB
Lancet Oncol; 2001 May; 2(5):290-7. PubMed ID: 11905784
[TBL] [Abstract][Full Text] [Related]
6. Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
Grothey A; Marshall JL
Oncology (Williston Park); 2007 Apr; 21(5):553-64, 566; discussion 566-8, 577-8. PubMed ID: 17536342
[TBL] [Abstract][Full Text] [Related]
7. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Nipp RD; Ryan DP
Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
9. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
[No Abstract] [Full Text] [Related]
10. [Systemic treatment of colorectal cancers--factual standards and perspectives].
Miron L
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):752-8. PubMed ID: 14756014
[TBL] [Abstract][Full Text] [Related]
11. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
Dy GK; Krook JE; Green EM; Sargent DJ; Delaunoit T; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pockaj BA; Sticca RP; Alberts SR; Pitot HC; Goldberg RM;
J Clin Oncol; 2007 Aug; 25(23):3469-74. PubMed ID: 17687151
[TBL] [Abstract][Full Text] [Related]
12. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Cassidy J
Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
[No Abstract] [Full Text] [Related]
13. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Hebbar M; Tournigand C; Lledo G; Mabro M; André T; Louvet C; Aparicio T; Flesch M; Varette C; de Gramont A;
Cancer Invest; 2006 Mar; 24(2):154-9. PubMed ID: 16537184
[TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
Jensen NF; Smith DH; Nygård SB; Rømer MU; Nielsen KV; Brünner N
Scand J Gastroenterol; 2012 Mar; 47(3):340-55. PubMed ID: 22181013
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for metastatic colorectal cancer.
Drug Ther Bull; 2002 Jul; 40(7):49-52. PubMed ID: 12154490
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
[TBL] [Abstract][Full Text] [Related]
17. Second-line therapy in colorectal cancer.
Berlin J
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):21-6. PubMed ID: 11204658
[TBL] [Abstract][Full Text] [Related]
18. Induction therapy in patients with metastatic colorectal cancer.
Venook AP
Semin Oncol; 2003 Aug; 30(4 Suppl 12):25-9. PubMed ID: 14508724
[No Abstract] [Full Text] [Related]
19. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]